Last update Nov. 27, 2019

Десвенлафаксина Суксинат

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

It is a reuptake-inhibitor of Serotonin and Norepinephrine, and active metabolite of Venlafaxine.
Oral administration once a day.

It is excreted in low amount into breast milk (Ilett 2010, Rampono 2004). The amount detected in the infant's plasma is in the range of 2% - 6% respective to the amount found in the mother's plasma (Ilett 2010, Rampono 2004).
Not relevant side-effects have been found in such infants (Rampono 2004).

Various medical societies and expert consensus consider the use of this medication compatible with breastfeeding (Hale 2019, Rowe 2013).


See below the information of these related products:

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Десвенлафаксина Суксинат is Desvenlafaxine Succinate in Cyrillic.

Is written in other languages:

Десвенлафаксина Суксинат is also known as

Group

Десвенлафаксина Суксинат belongs to this group or family:

Tradenames

Main tradenames from several countries containing Десвенлафаксина Суксинат in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 80 %
Molecular weight 400 daltons
Protein Binding 30 %
VD 3.4 l/Kg
pKa 10.1 -
Tmax 6 - 7.5 hours
T½ 11 hours
M/P ratio 2.8 -
Theoretical Dose 0.08 - 0.29 mg/Kg/d
Relative Dose 1.5 - 7.8 %

References

  1. AEMPS-Pfizer. Desvenlafaxina. Ficha técnica. 2019 Full text (in our servers)
  2. Sriraman NK, Melvin K, Meltzer-Brody S. ABM Clinical Protocol #18: Use of Antidepressants in Breastfeeding Mothers. Breastfeed Med. 2015 Abstract Full text (link to original source) Full text (in our servers)
  3. Pfizer. Desvenlafaxine. Drug Summary. 2014 Full text (in our servers)
  4. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  5. Rampono J, Teoh S, Hackett LP, Kohan R, Ilett KF. Estimation of desvenlafaxine transfer into milk and infant exposure during its use in lactating women with postnatal depression. Arch Womens Ment Health. 2011 Abstract
  6. Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S. Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Ther Drug Monit. 2010 Abstract
  7. Newport DJ, Ritchie JC, Knight BT, Glover BA, Zach EB, Stowe ZN. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. J Clin Psychiatry. 2009 Abstract

Total visits

1,494

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM